Clarivate Epidemiology’s coverage of upper tract urothelial carcinoma (UTUC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of upper tract urothelial carcinoma (UTUC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of upper tract urothelial carcinoma (UTUC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of upper tract urothelial carcinoma (UTUC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country…
